Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | BCHE | P06276 | 5/20 | 0.49 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18791198 | 0.92 | ALDH1A1 (0.59) | ALDH1A1KDM4EHSD17B10TSHRHPGD | |
| SCHEMBL1384956 | 0.91 | ALDH1A1 (0.56) | ALDH1A1KDM4EHSD17B10TSHRHPGD | |
| Avanbulin SCHEMBL1160317 | 0.91 | KDM4E (0.56) | ALDH1A1KDM4EHSD17B10TSHRHPGD | |
| SCHEMBL11301075 | 0.91 | ALDH1A1 (0.56) | ALDH1A1KDM4EHSD17B10TSHRHPGD | |
| Avanbulin SCHEMBL29374555 | 0.91 | KDM4E (0.56) | ALDH1A1KDM4EHSD17B10TSHRHPGD | |
| Avanbulin SCHEMBL9099635 | 0.90 | KDM4E (0.55) | ALDH1A1KDM4EHSD17B10TSHRHPGD | |
| Hydrochloric Acid SCHEMBL9099622 | 0.90 | ALDH1A1 (0.55) | ALDH1A1KDM4EHSD17B10TSHRHPGD | |
| SCHEMBL1383969 | 0.90 | KDM4E (0.56) | ALDH1A1KDM4EHSD17B10TSHRHPGD | |
| SCHEMBL1386947 | 0.89 | ALDH1A1 (0.56) | ALDH1A1KDM4EHSD17B10TSHRHPGD | |
| SCHEMBL30268967 | 0.88 | BCHE (0.55) | ALDH1A1KDM4EHSD17B10TSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4829791-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | claimed |
| US-20070043061-A1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG | 2007-02-22 | — | — | US | claimed |
| JP-2006528238-A | — | — | 2006-12-14 | — | — | JP | claimed |
| EP-1636215-A1 | FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2006-03-22 | — | — | EP | claimed |
| WO-2004103994-A1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-02 | — | — | WO | claimed |
| US-RE42890-E1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-7385061-B2 | 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-3-yl]-N-(2-cyanoethyl)-amine; treatment of neoplastic and autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2008-06-10 | — | — | US | disclosed |
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20070043061-A1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG | 2007-02-22 | — | — | US | disclosed |
| EP-1636215-A1 | FURAZANOBENZIMIDAZOLES | Basilea Pharmaceutica AG (CH) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004103994-A1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043061-A1 | Furazanobenzimidazoles | FOXO1, CYP2F1, OXER1 | ALDH1A1 335/4885KDM4E 1039/4885HSD17B10 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.